What matters

In a November 4, 2026 notice, the Federal Motor Carrier Safety Administration announced exemptions allowing 11 individuals with seizure histories to operate commercial motor vehicles in interstate commerce. The exemptions apply from July 1, 2026, through July 1, 2028, subject to medical monitoring, reporting requirements and possible early revocation.

Verified facts

  • FMCSA announced a final decision exempting 11 individuals from the interstate commercial motor vehicle medical qualification rule concerning epilepsy and seizure disorders. The decision applies to those individuals, not drivers with seizure disorders generally.
  • According to the notice, the exemptions from 49 CFR 391.41(b)(8) became applicable on July 1, 2026, and expire on July 1, 2028.
  • FMCSA said the 11 applicants had been seizure-free for periods ranging from four to 24 years while taking anti-seizure medication.
  • The agency said each applicant had maintained a stable medication treatment regimen for the preceding two years.
  • During the exemption period, each driver must report any seizure or change in treatment regimen to FMCSA within 24 hours.
  • Each driver must submit annual reports from their treating physician attesting that treatment remains stable and that the driver has remained seizure-free.
  • FMCSA makes the exemptions conditional on compliance and can revoke them for noncompliance. Conditions include remaining seizure-free, maintaining stable treatment, annual medical examinations and certified driving records, retaining annual medical certification in the driver’s qualification file, and carrying the exemption while driving. Drivers must report qualifying crashes and citations or convictions for disqualifying offenses within seven days and meet applicable commercial driver’s license testing requirements.

Analysis

Scope: This is a time-limited authorization for 11 individuals, not a general removal of the seizure-disorder qualification rule. The medical histories described by FMCSA concern periods before the decision; the annual reports and rapid-notification duties concern continued eligibility. Those are distinct from measured safety results during the exemption period.

Editorial opinion

VERXERA opinion: The evidence supports describing this decision as conditional permission for 11 drivers, rather than an unrestricted waiver. FMCSA reports four to 24 seizure-free years while taking medication and two years of stable treatment; it also requires annual physician reports and notification within 24 hours of a seizure or treatment change. Connecting those facts matters because the authorization running from July 1, 2026, to July 1, 2028, rests on both medical history and continuing obligations. The material limitation is that those histories and requirements do not establish safety outcomes throughout the exemption period. The notice’s detailed conditions are the relevant focus for readers seeking a fuller understanding of the authorization.

This is VERXERA’s editorial interpretation, separated from the facts and analysis above. The reader keeps the final judgment.

Counterevidence and limits

This report rests on FMCSA’s notice; the medical histories, dates and exemption conditions are the agency’s statements.

Known uncertainties

The notice does not establish safety outcomes for the full July 1, 2026–July 1, 2028 exemption period.